TransMedics Group, Inc. Forecast, price target & analysts
TransMedics Group, Inc. Target price 2025 - Analyst rating & recommendation
TransMedics Group, Inc. Classifications & Recommendation:
TransMedics Group, Inc. Price Target
| Target Price | $102.38 |
| Price | $72.12 |
| Potential |
41.95%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target TransMedics Group, Inc. 2026 .
The average TransMedics Group, Inc. target price is $102.38.
This is
41.95%
register free of charge
$125.00
73.32%
register free of charge
$75.00
3.99%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend TransMedics Group, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the TransMedics Group, Inc. stock has an average upside potential 2026 of
41.95%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 241.62 | 429.58 |
| 158.53% | 77.79% | |
| EBITDA Margin | 3.63% | 16.90% |
| 112.44% | 366.14% | |
| Net Margin | -10.69% | 7.48% |
| 75.79% | 169.94% |
10 Analysts have issued a sales forecast TransMedics Group, Inc. 2024 . The average TransMedics Group, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an TransMedics Group, Inc. EBITDA forecast 2024. The average TransMedics Group, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 TransMedics Group, Inc. Analysts have issued a net profit forecast 2024. The average TransMedics Group, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.77 | 0.96 |
| 37.40% | 224.68% | |
| P/E | 77.06 | |
| EV/Sales | 6.20 |
7 Analysts have issued a TransMedics Group, Inc. forecast for earnings per share. The average TransMedics Group, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the TransMedics Group, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
TransMedics Group, Inc....
Current TransMedics Group, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 05 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Dec 17 2024 |
| Baird | Locked ➜ Locked | Locked | Dec 11 2024 |
| Needham | Locked ➜ Locked | Locked | Dec 11 2024 |
| Piper Sandler | Locked ➜ Locked | Locked | Dec 11 2024 |
| Oppenheimer | Locked ➜ Locked | Locked | Dec 03 2024 |
| Needham | Locked ➜ Locked | Locked | Dec 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 05 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Dec 17 2024 |
|
Locked
Baird: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Dec 03 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
